IOVA Butterfly Strategy
IOVA (Iovance Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
IOVA (Iovance Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.31B, a beta of 0.69 versus the broader market, a 52-week range of 1.64-5.63, average daily share volume of 17.3M, a public-listing history dating back to 2010, approximately 838 full-time employees. These structural characteristics shape how IOVA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.69 indicates IOVA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a butterfly on IOVA?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current IOVA snapshot
As of May 15, 2026, spot at $3.46, ATM IV 97.43%, IV rank 16.40%, expected move 27.93%. The butterfly on IOVA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this butterfly structure on IOVA specifically: IOVA IV at 97.43% is on the cheap side of its 1-year range, which favors premium-buying structures like a IOVA butterfly, with a market-implied 1-standard-deviation move of approximately 27.93% (roughly $0.97 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IOVA expiries trade a higher absolute premium for lower per-day decay. Position sizing on IOVA should anchor to the underlying notional of $3.46 per share and to the trader's directional view on IOVA stock.
IOVA butterfly setup
The IOVA butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IOVA near $3.46, the first option leg uses a $3.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IOVA chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IOVA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.29 | N/A |
| Sell 2 | Call | $3.46 | N/A |
| Buy 1 | Call | $3.63 | N/A |
IOVA butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
IOVA butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on IOVA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on IOVA
Butterflies on IOVA are pinning bets - traders use them when they expect IOVA to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
IOVA thesis for this butterfly
The market-implied 1-standard-deviation range for IOVA extends from approximately $2.49 on the downside to $4.43 on the upside. A IOVA long call butterfly is a pinning play: it pays maximum at the middle strike if IOVA settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current IOVA IV rank near 16.40% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IOVA at 97.43%. As a Healthcare name, IOVA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IOVA-specific events.
IOVA butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IOVA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IOVA alongside the broader basket even when IOVA-specific fundamentals are unchanged. Always rebuild the position from current IOVA chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on IOVA?
- A butterfly on IOVA is the butterfly strategy applied to IOVA (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With IOVA stock trading near $3.46, the strikes shown on this page are snapped to the nearest listed IOVA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IOVA butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the IOVA butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 97.43%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IOVA butterfly?
- The breakeven for the IOVA butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IOVA market-implied 1-standard-deviation expected move is approximately 27.93%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on IOVA?
- Butterflies on IOVA are pinning bets - traders use them when they expect IOVA to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current IOVA implied volatility affect this butterfly?
- IOVA ATM IV is at 97.43% with IV rank near 16.40%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.